Keywords
Eligibility Determination ×
Leukemia ×
Show more Keywords
Table of contents
  1. 1. Clinical Trial
  2. 2. Routine Documentation
  3. 3. Registry/Cohort Study
  4. 4. Quality Assurance
  5. 5. Data Standard
  6. 6. Patient-Reported Outcome
  7. 7. Medical Specialty
Selected data models

You must log in to select data models for download or further analysis.

82 Search results.

Eligibility Leukemia NCT02420717

- 4/26/19 - 1 form, 2 itemgroups, 28 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria
Ruxolitinib or Dasatinib With Chemotherapy in Patients With Philadelphia Chromosome (Ph)-Like Acute Lymphoblastic Leukemia (ALL); ODM derived from: https://clinicaltrials.gov/show/NCT02420717

Eligibility Leukemia NCT02419469

- 4/26/19 - 1 form, 2 itemgroups, 16 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria
Augmented Berlin-Frankfurt-Munster Therapy Plus Ofatumumab for Young Adults With Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma; ODM derived from: https://clinicaltrials.gov/show/NCT02419469

Eligibility Leukemia NCT02392572

- 4/26/19 - 1 form, 2 itemgroups, 15 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria
ONC201 in Relapsed/Refractory Acute Leukemias and High-risk Myelodysplastic Syndromes (HR-MDS); ODM derived from: https://clinicaltrials.gov/show/NCT02392572

Eligibility Leukemia NCT02349698

- 4/25/19 - 1 form, 2 itemgroups, 20 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria
A Clinical Research of CAR T Cells Targeting CD19 Positive Malignant B-cell Derived Leukemia and Lymphoma; ODM derived from: https://clinicaltrials.gov/show/NCT02349698

Eligibility Leukemia NCT02331706

- 4/25/19 - 1 form, 2 itemgroups, 14 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria
IFN-DLI for Relapsed Acute Leukemia After Allo-SCT; ODM derived from: https://clinicaltrials.gov/show/NCT02331706

Eligibility Leukemia NCT02083250

- 4/25/19 - 1 form, 2 itemgroups, 18 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria
Fludarabine/Clofarabine/Busulfan Combined With SAHA in Acute Leukemia; ODM derived from: https://clinicaltrials.gov/show/NCT02083250

Eligibility Refractory TdT-Positive Leukemia NCT00709215

- 9/25/18 - 1 form, 2 itemgroups, 19 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria
Study of Cordycepin Plus Pentostatin in Patients With Refractory TdT-Positive Leukemia; ODM derived from: https://clinicaltrials.gov/show/NCT00709215

Eligibility Refractory Leukemia NCT00880269

- 9/25/18 - 1 form, 2 itemgroups, 15 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria
Efficacy and Safety of Panobinostat (LBH5789) in Patients With Refractory de Novo or Secondary Acute Myelogenous Leukemia (AML); ODM derived from: https://clinicaltrials.gov/show/NCT00880269

Eligibility Leukemia NCT01050764

- 5/23/18 - 1 form, 1 itemgroup, 25 items, 1 language
Itemgroup: Criteria
Haploidentical Allogeneic Transplant w/Post Transplant Infusion of Regulatory T-cells (BMT Protocol 204); ODM derived from: https://clinicaltrials.gov/show/NCT01050764

Eligibility Leukemia NCT01038635

- 5/22/18 - 1 form, 2 itemgroups, 19 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria
5-Azacytidine With Lenalidomide in Patients With High Risk Myelodysplastic Syndrome (MDS) and Acute Myelogenous Leukemia (AML); ODM derived from: https://clinicaltrials.gov/show/NCT01038635

Eligibility Leukemia NCT00990249

- 5/22/18 - 1 form, 2 itemgroups, 15 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria
Busulfan Plus Clofarabine Followed by Allogeneic Hematopoietic Stem Cell Transplantation; ODM derived from: https://clinicaltrials.gov/show/NCT00990249

Eligibility Leukemia NCT00897182

- 5/19/18 - 1 form, 1 itemgroup, 11 items, 1 language
Itemgroup: Criteria
Identifying Cancer Genes in in Blood and Bone Marrow Samples From Patients With Acute Myeloid Leukemia; ODM derived from: https://clinicaltrials.gov/show/NCT00897182